Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $149,776.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Friday, January 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00.
• On Tuesday, December 10th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $59.46, for a total transaction of $130,812.00.

Corcept Therapeutics Stock Performance

NASDAQ CORT opened at $72.72 on Friday. Corcept Therapeutics Incorporated has a 52-week low of $20.84 and a 52-week high of $74.61. The company has a 50-day simple moving average of $57.97 and a 200 day simple moving average of $49.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The company has a market capitalization of $7.62 billion, a PE ratio of 57.71 and a beta of 0.58.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CORT. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a report on Friday, February 7th. Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Finally, Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Buy” and a consensus price target of $88.25.

Hedge Funds Weigh In On Corcept Therapeutics

Several large investors have recently modified their holdings of CORT. Capital Performance Advisors LLP purchased a new position in shares of Corcept Therapeutics in the third quarter worth about $25,000. Kestra Investment Management LLC purchased a new position in shares of Corcept Therapeutics in the fourth quarter worth about $27,000. Canada Pension Plan Investment Board purchased a new position in shares of Corcept Therapeutics in the fourth quarter worth about $40,000. National Bank of Canada FI purchased a new position in shares of Corcept Therapeutics in the fourth quarter worth about $42,000. Finally, USA Financial Formulas purchased a new position in shares of Corcept Therapeutics in the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.